Northern Venture Trust PLC
Northern Venture Trust PLC is a Venture Capital Trust established under the legislation introduced in the Finance Act 1995. The company’s principal objective is to invest in a portfolio of quoted and unquoted shares and securities which will, through a combination of income yield and capital growth, provide high long-term returns to shareholders.
Northern Venture Trust was formed in 1995.
The company’s share price is carried daily in the Financial Times (under “Investment Companies - VCTs”), the Daily Telegraph, the Newcastle Journal and the Herald. To obtain an updated share price please click here. Share price information is provided by the London Stock Exchange plc whose terms and conditions you will be required to accept in order to view the information.
The company’s financial calendar for the year ending 30 September 2010 is as follows:
May 2010 Half-yearly financial report for the six months to 31 March 2010 published
June 2010 Interim dividend paid
November 2010 Results for year to 30 September 2010 announced
December 2010 Annual report and financial statements published
January 2011 Annual general meeting (Edinburgh); final dividend paid
Northern Venture Trust PLC is a member of the Association of Investment Companies.
If you would like to receive a copy of the latest published annual report and accounts or half-yearly financial report, by post, please contact us. If you would like to download reports in PDF format, please click here.
Directors
Registrars:
- Equiniti Limited (for further information please click here)
Auditors:
- KPMG Audit Plc
Latest news
VCT for income: Northern 3 VCT 15 million share issue offer
Northern 3 VCT PLC has launched a public offer of 15 million new ordinary shares. For further information & the prospectus click here.
Abermed sold to
International SOS
NVM has sold its investment in Abermed, the UK occupational health and remote medical services company, to International SOS, the world's leading provider of integrated medical and security assistance, for an undisclosed consideration. For further information click here.
DxS sold to Qiagen –
record exit for NVM
NVM has sold DxS to Qiagen to create a global leader in personalised medicine for a value of $130 million ($95 million initial consideration plus earnouts of up to $35 million). For further information click here.